- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06190145
Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia
December 19, 2023 updated by: Xiao Hui Zhang, Peking University People's Hospital
A Single-arm, Open-label Phase II Study to Determine the Safety and Efficacy of Teriflunomide in Patients With Steroid-resistant/Relapse Thrombocytopenia
Single-arm, open-label, single-center study to evaluate the efficacy and safety of teriflunomide for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
Study Overview
Detailed Description
This is a prospective, single-arm, open-label study of teriflunomide in approximately 40 patients with ITP who have relapsed or have an insufficient response to prior therapies.
Teriflunomide is administered as 7 mg orally once daily with dose adjustments for 24 weeks.
Efficacy and safety outcomes are assessed on scheduled study visits.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiao-Hui Zhang, MD
- Phone Number: +8613522338836
- Email: zhangxh100@sina.com
Study Contact Backup
- Name: Li-Ping Yang, MD
- Phone Number: +8618519172033
- Email: lpyangvip@163.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Insititute of Hematology, Peking University People's Hospital
-
Contact:
- Xiao-Hui Zhang, MD
- Phone Number: +8613522338836
- Email: zhangxh100@sina.com
-
Contact:
- Li-Ping Yang, MD
- Phone Number: +8618519172033
- Email: lpyangvip@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of primary immune thrombocytopenia (ITP) by excluding other supervened causes of thrombocytopenia
- Patients with a platelet count <30,000/μL or a platelet count <50,000/μL with bleeding manifestations at the enrollment;
- Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid tapering or after its discontinuation;
- Willing and able to sign written informed consent.
Exclusion Criteria:
- Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit;
- Secondary immune thrombocytopenia (e.g. patients with HIV, HCV, Helicobacter pylori infection, malignancy, or patients with confirmed autoimmune disease);
- Pregnancy or lactation;
- Pre-existing acute or chronic liver disease, or serum alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (ULN);
- Current or recent (< 4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection;
- Have evidence of active tuberculosis (TB), or have previously had evidence of active TB and did not receive appropriate and documented treatment, or have had household contact with a person with active TB and did not receive appropriate and documented prophylaxis for TB;
- Patients who are deemed unsuitable for the study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Teriflunomide
Oral Teriflunomide is given at a dose of 7 mg once daily with dose adjustments for 24 weeks.
Treatment was discontinued if a dose-limiting toxic effect occurred, rescue medication was used, or concomitant medication for immune thrombocytopenia was changed beyond the 10% level as defined above.
|
Starting dose of 7 mg once daily.
Dose adjustments were made throughout the study based on individual platelet counts.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sustained response
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
Platelet count over 30,000/μL and at least a 2-fold increase of the baseline count in the absence of bleeding and rescue therapy for at least four of the six visits between weeks 19 and 24.
|
From the start of study treatment (Day 1) to the end of week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
Complete response (CR) was defined as platelet count over 100,000/μL and absence of bleeding.
Response (R) was defined as platelet count over 30,000/μL and at least a 2-fold increase of the baseline count and absence of bleeding.
|
From the start of study treatment (Day 1) to the end of week 24
|
Time to response
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
The time from treatment initiation to achieve a CR or a R.
|
From the start of study treatment (Day 1) to the end of week 24
|
Initial response
Time Frame: From the start of study treatment (Day 1) up to week 4 of treatment
|
The number of participants with achievement of CR or R at 4 weeks.
|
From the start of study treatment (Day 1) up to week 4 of treatment
|
Bleeding events
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
Clinically significant bleeding was assessed using the World Health Organization (WHO) bleeding scale.
|
From the start of study treatment (Day 1) to the end of week 24
|
Health-related quality of life (HRQoL)
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
ITP-PAQ was used to assess the Health-Related Quality of Life (HRQoL) before and after treatment.
|
From the start of study treatment (Day 1) to the end of week 24
|
Adverse events
Time Frame: From the start of study treatment (Day 1) to the end of week 24
|
Adverse events (AEs) were reported and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
|
From the start of study treatment (Day 1) to the end of week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiao-Hui Zhang, Peking University Institute of Hematology, Peking University People's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2023
Primary Completion (Estimated)
October 15, 2024
Study Completion (Estimated)
June 15, 2025
Study Registration Dates
First Submitted
December 19, 2023
First Submitted That Met QC Criteria
December 19, 2023
First Posted (Actual)
January 5, 2024
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
December 19, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Teriflunomide
Other Study ID Numbers
- PKU-TFITP-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAdult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimeticsItaly
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
European Research Consortium on ITPFondazione Progetto EmatologiaCompletedPrimary Immune Thrombocytopenia (ITP)Spain, Switzerland, United Kingdom, Italy, France, Norway
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune
-
Nahda UniversityRecruiting
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
Clinical Trials on Teriflunomide
-
Kyowa Kirin, Inc.University of New Mexico Cancer CenterNo longer availableGlioblastoma Multiforme
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
SanofiActive, not recruitingRelapsing Multiple SclerosisSpain, United States, Mexico, Japan, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Italy, Lithuania, Poland, Romania, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, Hong Kong
-
Kyowa Kirin, Inc.CompletedCarcinoma | Cancer | Solid TumorUnited States, France
-
Novartis PharmaceuticalsCompletedRelapsing Multiple ScelrosisUnited States, Austria, Belgium, Croatia, Germany, Taiwan, Canada, Czechia, Spain, Argentina, Australia, Peru, South Africa, United Kingdom, Bulgaria, Latvia, Lithuania, Russian Federation, India, Portugal, Italy, Turkey, Finland, France and more
-
SanofiActive, not recruitingRelapsing Multiple SclerosisUnited States, Argentina, Belgium, Brazil, Canada, Chile, Croatia, Czechia, France, Germany, Greece, Hungary, India, Israel, Korea, Republic of, Latvia, Netherlands, Norway, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, Spai... and more
-
SanofiCompletedMultiple SclerosisCanada, France
-
SanofiCompletedMultiple SclerosisUnited States, Austria, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
-
SanofiCompletedMultiple SclerosisUkraine, Russian Federation, Estonia, Czech Republic, Denmark, Finland, France, Turkey, United Kingdom, United States, Portugal, Austria, Canada, Chile, Germany, Italy, Netherlands, Norway, Poland, Sweden, Switzerland
-
Novartis PharmaceuticalsCompletedRelapsing Multiple SclerosisBelgium, Italy, United States, Croatia, Spain, Netherlands, Switzerland, Thailand, Israel, Czechia, Estonia, Poland, France, Bulgaria, Russian Federation, Germany, Turkey, Slovakia, Australia, Denmark, Greece, Argentina, India, Hungary, United Kingdom and more